History | Patisiran for treating hereditary transthyretin amyloidosis | Guidance | NICE

History

Documents created during the development process.

Expected publication

Equality Impact Assessment (Guidance development) (PDF 164 KB)

Published:

14 August 2019

Final evaluation determination

Final evaluation determination
Final evaluation determination document (MSWord 81 KB)

Published:

08 July 2019
Committee papers 12 February 2019 (PDF 954 KB)

Published:

08 July 2019
Public committee slides 12 February 2019 (PDF 288 KB)

Published:

08 July 2019
Committee papers 21 May 2019 (PDF 912 KB)

Published:

08 July 2019
Public committee slides 21 May 2019 (PDF 1.05 MB)

Published:

08 July 2019

Notes

Note

Evaluation consultation

Evaluation consultation
Evaluation consultation document (PDF 441 KB)

Published:

12 December 2018
Committee papers (PDF 6.72 MB)

Published:

12 December 2018
Public committee slides (PDF 1016 KB)

Published:

12 December 2018

Invitation to participate

Final matrix (PDF 288 KB)

Published:

18 June 2018
Final scope (PDF 215 KB)

Published:

18 June 2018
NICE's response to comments on the draft scope and provisional matrix (PDF 685 KB)

Published:

18 June 2018
Equality impact assessment (Scoping) (PDF 177 KB)

Published:

18 June 2018

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

Draft scope pre referral (PDF 228 KB)

Published:

29 November 2017
Draft matrix pre referral (PDF 285 KB)

Published:

29 November 2017